Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$162.47 USD

162.47
423,386

-1.75 (-1.07%)

Updated Sep 18, 2024 03:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

MASI Stock Gains as US Court Raises Concern About Politan's Ethics

by Zacks Equity Research

Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept. 19.

Stryker Stock Declines Despite Completion of care.ai Acquisition

by Zacks Equity Research

SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.

DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

In the most recent trading session, DaVita HealthCare (DVA) closed at $164.22, indicating a -0.59% shift from the previous trading day.

Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS

by Zacks Equity Research

MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan

by Zacks Equity Research

The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.

Zacks Investment Ideas feature highlights: Intuitive Surgical, SharkNinja and DaVita

by Zacks Equity Research

Intuitive Surgical, SharkNinja and DaVita have been highlighted in this Investment Ideas article.

Nilanjan Choudhury headshot

5 Stocks to Benefit From Relative Price Strength Trends

by Nilanjan Choudhury

LMB, UI, RCL, DVA and BOOT are five stocks with explosive relative price strength.

Derek Lewis headshot

3 Red Hot Stocks Flashing Buy Signals: DVA, ISRG, SN

by Derek Lewis

Stocks making new highs tend to make even higher highs, particularly when positive earnings estimate revisions hit the tape. And that's precisely what these three companies have seen.

DaVita Inc. (DVA) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Reasons to Retain Inari Medical Stock in Your Portfolio for Now

by Zacks Equity Research

NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio

by Zacks Equity Research

Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.

Factors Driving Veeva Stock More Than 20% in Three Months

by Zacks Equity Research

Robust quarterly results on the back of new partnerships and rising subscription revenues are driving VEEV's shares.

Here's Why DaVita HealthCare (DVA) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $153.99, denoting a +0.29% change from the preceding trading day.

Are Investors Undervaluing DaVita (DVA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Medical Stocks Lagging Adagene (ADAG) This Year?

by Zacks Equity Research

Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Glaukos Stocks Rides on Strong Product Demand Amid Competition

by Zacks Equity Research

GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

MASI Stock Down Despite New SafetyNet Deal for Neonatal Care

by Zacks Equity Research

The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.

DaVita HealthCare (DVA) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

DaVita HealthCare (DVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here's Why You Should Retain PDCO Stock in Your Portfolio for Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies on the back of its broad product line.

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

VEEV Stock Up Following the Release of New Features of Veeva Site Connect

by Zacks Equity Research

Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.

COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD

by Zacks Equity Research

Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.

DaVita and Potlatch have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

DaVita and Potlatch are part of the Zacks Bull and Bear of the Day article.